cassis26
$ZNTL I think people are missing the forest for the trees. Azenosertib isn't just an ovarian cancer therapy — I suspect it's being positioned to become an ADC platform enabler across multiple tumor types.
My bet? The newly announced planned TNBC combination involves Enhertu (T-DXd), which is already being investigated alongside azenosertib in an NCI-sponsored trial (NCT06364410). That study has been underway for nearly two years, potentially generating valuable early clinical insights.
The bigger opportunity may not be PROC alone, but an entire franchise built around enhancing the efficacy of ADCs.
AstraZeneca spent nearly a decade trying to develop its own WEE1 inhibitor. They also recently invested $2 BILLION in Summit Therapeutics alongside an ADC collaboration recently. Imagine what a clinically validated WEE1–ADC platform could be worth.
AbbVie acquired mirvetuximab for $10 BILLION. Same indication as ZNTL. and that's just one indication. Asymetic Risk\reward here
Long $ZNTL.
2

:format(webp)/https%3A%2F%2Fstaticx-tuner.zacks.com%2Fimages%2Farticles%2Fmain%2F08%2F595.jpg)